Abstract
No information is available on the clinical use of binimetinib during breastfeeding. Because binimetinib is 97% bound to plasma proteins, and the half-life of the drug is 3.5 hours, the amount in milk is likely to be low. However, the manufacturer recommends that breastfeeding be discontinued during binimetinib therapy and for at least 3 days after the final dose. For patients taking the combination with encorafenib, the manufacturer recommends that breastfeeding be discontinued during binimetinib therapy and for at least 2 weeks after the final dose.
摘要
关于比美替尼在母乳喂养期间的临床应用尚无可用信息。由于比美替尼与血浆蛋白的结合率为97%，且药物半衰期为3.5小时，因此乳汁中的含量可能较低。然而，制造商建议在比美替尼治疗期间以及最后一剂后至少3天内停止母乳喂养。对于接受比美替尼与恩考芬尼联合治疗的患者，制造商建议在比美替尼治疗期间以及最后一剂后至少2周内停止母乳喂养。
相似文献
8
Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report.一例使用恩考芬尼、比美替尼和西妥昔单抗治疗的BRAF V600E突变转移性结直肠癌患者出现严重症状性心脏功能障碍：病例报告
J Pharm Health Care Sci. 2025 Sep 1;11(1):80. doi: 10.1186/s40780-025-00480-z.
10
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.用于降低人类免疫缺陷病毒感染母婴传播风险的抗逆转录病毒药物。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003510. doi: 10.1002/14651858.CD003510.pub2.
Zotero 插件